With that in mind, let's take a closer look at Gilead, and see what CAPS investors are saying about the stock right now.
Foster City, Calif. (1987)
Chairman/CEO John Martin
President/COO John Milligan
$1.9 billion / $8.0 billion
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 2,253 members who have rated Gilead believe the stock will outperform the S&P 500 going forward.
Very profitable company, and I expect [Gilead's] streak of profitability to continue to increase. No significant patent expiration until 2018. With the current success in the HIV market, if the company can find success in a new category via R&D efforts, this could turn out to be a big winner.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Gilead may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
The article Why Gilead Sciences Is Poised to Keep Poppin' originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.